Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $25.67

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have received a consensus recommendation of “Buy” from the eight brokerages that are covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $25.67.

Several research firms recently commented on ATXS. Oppenheimer raised their target price on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. Citizens Jmp upgraded shares of Astria Therapeutics to a “strong-buy” rating in a report on Friday, January 31st. JMP Securities initiated coverage on Astria Therapeutics in a research report on Friday, January 31st. They issued an “outperform” rating and a $26.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research report on Thursday, February 27th.

Hedge Funds Weigh In On Astria Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC raised its holdings in shares of Astria Therapeutics by 29.2% during the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after acquiring an additional 1,767,714 shares in the last quarter. RA Capital Management L.P. raised its stake in shares of Astria Therapeutics by 1.2% during the 3rd quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock worth $56,208,000 after purchasing an additional 61,457 shares in the last quarter. Vestal Point Capital LP raised its stake in shares of Astria Therapeutics by 4.5% during the 4th quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company’s stock worth $37,369,000 after purchasing an additional 180,000 shares in the last quarter. Fcpm Iii Services B.V. acquired a new stake in shares of Astria Therapeutics during the 4th quarter valued at about $25,680,000. Finally, Vanguard Group Inc. grew its stake in shares of Astria Therapeutics by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 2,677,353 shares of the biotechnology company’s stock valued at $23,936,000 after buying an additional 41,833 shares in the last quarter. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Astria Therapeutics Stock Performance

Shares of NASDAQ:ATXS opened at $6.42 on Tuesday. The company’s fifty day moving average is $7.50 and its two-hundred day moving average is $9.79. Astria Therapeutics has a 1-year low of $5.84 and a 1-year high of $16.90. The stock has a market capitalization of $362.31 million, a price-to-earnings ratio of -3.07 and a beta of 0.69.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.